Chugai Pharmaceuticals (4519-TO)

GenEng News  Dec 22  Comment 
Chugai Pharmaceutical is paying PharmaMar €30 million ($31.4 million) upfront for Japanese rights to the latter’s Phase III-stage, marine-derived anticancer drug PM1183 (lurbinectedin). The RNA polymerase II inhibitor is in development for the...
GenEng News  Nov 28  Comment 
Chugai Pharmaceutical has licensed out worldwide manufacturing, development, and marketing rights to its anticancer candidate PA799 to Menarini Group’s oncology-focused subsidiary Berlin-Chemie Menarini, the companies said today. The value...
FierceBiotech  Jul 21  Comment 
Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai ntaylor Thu, 07/21/2016 - 08:39

You may also be interested in articles related to Chugai Pharmaceuticals (4519-TO):
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki